/INAB
INAB Stock - IN8bio, Inc.
Healthcare|BiotechnologyNASDAQ
$1.21-12.32%
$0.17 (-12.32%) • Dec 19
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+230.6%upside
Target: $4.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for INAB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.20 – $1.22
TARGET (TP)$4.00
STOP LOSS$1.11
RISK/REWARD1:27.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.02
52W High$12.54
52W Low$1.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-2,501,000 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-30,437,000 | $-30,337,000 | $-28,521,000 | $-14,653,000 | $-8,557,000 |
| Net Income | $-30,437,000 | $-30,007,000 | $-28,521,000 | $-14,653,000 | $-8,557,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.57 | $-1.00 | $-1.36 | $-0.78 | $-0.53 |
Company Overview
IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation. It also develops INB-400 and INB-300 that is in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$11
Average Target
↑ 788.4% Upside
Now
$8
Low
$11
Average
$14
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| March 18th 2024 | Laidlaw | Initiation | Buy | $7.5 |
| August 30th 2022 | H.C. Wainwright | Initiation | Buy | $14 |
Earnings History & Surprises
INABBeat Rate
50%
Last 18 quarters
Avg Surprise
+2.3%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-0.85
Q4 2025
EPS Surprise History
Q1 24
-31.2%
$-0.21vs$-0.16
Q2 24
-17.6%
$-0.20vs$-0.17
Q3 24
-18.8%
$-0.19vs$-0.16
Q4 24
-7.1%
$-0.15vs$-0.14
Q1 25
+42.9%
$-0.04vs$-0.07
Q2 25
-16.7%
$-2.10vs$-1.80
Q3 25
+17.3%
$-1.24vs$-1.50
Q4 25
+29.2%
$-0.85vs$-1.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 12, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | $-1.20 | $-0.85 | +29.2% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-1.50 | $-1.24 | +17.3% | ✓ BEAT |
Q2 2025 | May 7, 2025 | $-1.80 | $-2.10 | -16.7% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.07 | $-0.04 | +42.9% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.17 | $-0.20 | -17.6% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.16 | $-0.21 | -31.2% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.28 | $-0.27 | +3.6% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.33 | $-0.30 | +9.1% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.28 | $-0.34 | -21.4% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.33 | $-0.38 | -15.2% | ✗ MISS |
Q2 2022 | May 12, 2022 | $-0.34 | $-0.33 | +2.9% | ✓ BEAT |
Q1 2022 | Mar 17, 2022 | $-0.21 | $-0.21 | 0.0% | = MET |
Q4 2021 | Nov 10, 2021 | $-0.33 | $-0.25 | +24.2% | ✓ BEAT |
Q3 2021 | Sep 10, 2021 | $-0.30 | $-0.16 | +45.8% | ✓ BEAT |
Q3 2021 | Jul 30, 2021 | — | $-0.16 | — | — |
Latest News
IN8bio Prices Private Placement For Gross Proceeds Up To $40.2M To Advance Novel Gamma-Delta T Cell Engager
📈 PositiveBenzinga•Dec 19, 2025, 01:07 PM
Shares of IN8bio are trading higher. The company announced consolidated data from its Phase 1 single-center clinical trial of INB-200 and Phase 2 multi-center trial of INB-400 for the treatment of patients with newly diagnosed glioblastoma at 2025 SNO Annual Meeting.
📈 PositiveBenzinga•Nov 24, 2025, 07:59 PM
IN8bio Presents Consolidated INB-200 Phase 1 And INB-400 Phase 2 Glioblastoma Data At 2025 SNO Annual Meeting
➖ NeutralBenzinga•Nov 24, 2025, 07:53 PM
IN8bio Inc Files For Mixed Shelf Offering Of Upto $200M
📉 NegativeBenzinga•Nov 7, 2025, 10:18 PM
IN8bio Q3 EPS $(0.85) Beats $(1.25) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 10:06 PM
Ohio State University Added As New Clinical Site In Ongoing Phase 1 Trial Of IN8bio's INB-100, Donor-Derived Allogeneic Gamma-Delta T Cell Therapy
📈 PositiveBenzinga•Oct 29, 2025, 12:05 PM
IN8bio Presents New Preclinical Data From Gamma-Delta T Cell Engager Program, INB-619, At 2025 ACR Convergence Meeting
➖ NeutralBenzinga•Oct 27, 2025, 12:12 PM
Frequently Asked Questions about INAB
What is INAB's current stock price?
IN8bio, Inc. (INAB) is currently trading at $1.21 per share. The stock has moved -12.32% today.
What is the analyst price target for INAB?
The average analyst price target for INAB is $4.00, based on 1 analyst.
What sector is IN8bio, Inc. in?
IN8bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is INAB's market cap?
IN8bio, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.
Does INAB pay dividends?
No, IN8bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
GLTO
Galecto, Inc.
$27.17
Mkt Cap: $0.0B
HCWB
HCW Biologics Inc.
$1.57
Mkt Cap: $0.0B
KPRX
Kiora Pharmaceuticals, Inc.
$2.16
Mkt Cap: $0.0B
LYRA
Lyra Therapeutics, Inc.
$3.60
Mkt Cap: $0.0B
PHIO
Phio Pharmaceuticals Corp.
$1.07
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to INAB for comparison